ArticleCancers2021

Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial.

Ashley M Hopkins et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.